CytoMed Therapeutics (GDTC) Non-Current Debt (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Non-Current Debt of $284446.8 for Q4 2025, down 23.64% sequentially from $372502.0 in Q2 2025, and down 4.04% YoY from $296433.0 in Q4 2024.
CytoMed Therapeutics (GDTC) Non-Current Debt (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Non-Current Debt for 5 years, with the latest figure at $284446.8 in Q4 2025.
- Quarterly Non-Current Debt fell 4.04% year-over-year to $284446.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $284446.8 (down 4.04% YoY) and the FY2025 annual result came in at $286691.0, down 2.88% from the prior year.
- Non-Current Debt declined to $284446.8 in Q4 2025 per GDTC's latest filing, from $372502.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $397270.9 in Q4 2021 and troughed at $4266.0 in Q2 2023.
- A 5-year average of $298208.4 and a median of $319926.3 in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt dropped 14.97% in 2022, then soared 9063.06% in 2024.
- Over 5 years, Non-Current Debt stood at $397270.9 in 2021, then decreased by 14.97% to $337818.9 in 2022, then fell by 10.59% to $302033.6 in 2023, then retreated by 1.85% to $296433.0 in 2024, then retreated by 4.04% to $284446.8 in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $284446.8, $372502.0, and $296433.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 8.96 Bn |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - | 284,446.85 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 284,446.85 |
| Jun 30, 2025 | 372,502.00 |
| Dec 31, 2024 | 296,432.97 |
| Jun 30, 2024 | 390,896.00 |
| Dec 31, 2023 | 302,033.65 |
| Jun 30, 2023 | 4,266.00 |
| Dec 31, 2022 | 337,818.90 |
| Dec 31, 2021 | 397,270.86 |